<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Sana Biotechnology, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/sana-biotechnology-inc</link>
    <description>Latest news and press releases for Sana Biotechnology, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 27 May 2026 20:05:05 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/sana-biotechnology-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bcb578dffbe2df116e57.webp</url>
      <title>Sana Biotechnology, Inc.</title>
      <link>https://6ix.com/company/sana-biotechnology-inc</link>
    </image>
    <item>
      <title>Sana Biotechnology to Present at June 2026 Investor Conferences</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-to-present-at-june-2026-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-to-present-at-june-2026-investor-conferences</guid>
      <pubDate>Wed, 27 May 2026 20:05:05 GMT</pubDate>
      <description>Sana Biotechnology to Present at June 2026 Investor</description>
    </item>
    <item>
      <title>Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-sale-of-approximately-dollar69-million-of-shares-through-its-at-the-market-atm-facility</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-sale-of-approximately-dollar69-million-of-shares-through-its-at-the-market-atm-facility</guid>
      <pubDate>Fri, 15 May 2026 13:00:00 GMT</pubDate>
      <description>SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the company’s common stock through its at-the-market (“ATM”) facility established through TD Securities (USA) LLC for net proceeds of approximately $69 million. The investment, including participation based on interest received from RA Capital Management, combined</description>
    </item>
    <item>
      <title>Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-presents-preclinical-data-for-in-vivo-car-t-cell-therapy-sg293-surrogate-demonstrating-cell-specific-delivery-potent-car-t-cell-generation-and-deep-b-cell-depletion-in-nhps</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-presents-preclinical-data-for-in-vivo-car-t-cell-therapy-sg293-surrogate-demonstrating-cell-specific-delivery-potent-car-t-cell-generation-and-deep-b-cell-depletion-in-nhps</guid>
      <pubDate>Tue, 12 May 2026 20:05:00 GMT</pubDate>
      <description>Data presented at the American Society of Gene &amp; Cell Therapy (ASGCT) 2026 Annual MeetingSEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent CAR T cell generation, and deep B cell depletion in non-human pri</description>
    </item>
    <item>
      <title>Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-reports-first-quarter-2026-financial-results-and-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-reports-first-quarter-2026-financial-results-and-business-updates</guid>
      <pubDate>Mon, 11 May 2026 04:00:00 GMT</pubDate>
      <description>Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress</description>
    </item>
    <item>
      <title>Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-to-present-at-the-bofa-securities-2026-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-to-present-at-the-bofa-securities-2026-healthcare-conference</guid>
      <pubDate>Tue, 05 May 2026 20:05:00 GMT</pubDate>
      <description>SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2026 Healthcare Conference at 2:20 p.m. PT on Tuesday, May 12, 2026. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sa</description>
    </item>
    <item>
      <title>Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene &amp; Cell Therapy (ASGCT) 2026 Annual Meeting</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-oral-presentation-highlighting-preclinical-data-from-in-vivo-car-t-sg293-at-the-american-society-of-gene-and-cell-therapy-asgct-2026-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-oral-presentation-highlighting-preclinical-data-from-in-vivo-car-t-sg293-at-the-american-society-of-gene-and-cell-therapy-asgct-2026-annual-meeting</guid>
      <pubDate>Mon, 27 Apr 2026 20:30:00 GMT</pubDate>
      <description>SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene &amp; Cell Therapy (ASGCT) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA. Oral Presentation: Title:Potent, safe, and cell-</description>
    </item>
    <item>
      <title>Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-and-mayo-clinic-announce-strategic-collaboration-focused-on-improving-care-in-type-1-diabetes-and-accelerating-development-of-sc451</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-and-mayo-clinic-announce-strategic-collaboration-focused-on-improving-care-in-type-1-diabetes-and-accelerating-development-of-sc451</guid>
      <pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
      <description>Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients</description>
    </item>
    <item>
      <title>Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-continued-positive-clinical-results-through-14-months-from-type-1-diabetes-study-of-islet-cell-transplantation-without-immunosuppression-650</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-continued-positive-clinical-results-through-14-months-from-type-1-diabetes-study-of-islet-cell-transplantation-without-immunosuppression-650</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression</description>
    </item>
    <item>
      <title>Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</guid>
      <pubDate>Tue, 03 Mar 2026 21:05:00 GMT</pubDate>
      <description>Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant New England Journal of Medicine published positive 12-week clinical results of the UP421 type 1 diabetes study Incorporating the tested hypoimmune technology to develop SC451, a hypoimmune-modified, stem cell-derived</description>
    </item>
    <item>
      <title>Sana Biotechnology to Present at March 2026 Investor Conferences</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-to-present-at-march-2026-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-to-present-at-march-2026-investor-conferences</guid>
      <pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
      <description>SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Sana will present at the Cowen 46th Annual Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026.Sana will present at the Citizens Life Sciences Conference at 1:40 p.m.</description>
    </item>
    <item>
      <title>Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-appoints-brian-piper-as-executive-vice-president-chief-financial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-appoints-brian-piper-as-executive-vice-president-chief-financial-officer</guid>
      <pubDate>Tue, 17 Feb 2026 14:00:00 GMT</pubDate>
      <description>SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-</description>
    </item>
    <item>
      <title>Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-present-44th-annual-212600942</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-present-44th-annual-212600942</guid>
      <pubDate>Wed, 07 Jan 2026 21:26:00 GMT</pubDate>
      <description>SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations</description>
    </item>
    <item>
      <title>Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-publication-nature-biotechnology-vivo-gene-editing-human</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-publication-nature-biotechnology-vivo-gene-editing-human</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using</description>
    </item>
    <item>
      <title>Sana Biotechnology to Present at December 2025 Investor Conferences</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-present-december-2025-investor-conferences-2025-11-24</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-present-december-2025-investor-conferences-2025-11-24</guid>
      <pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
      <description>SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered</description>
    </item>
    <item>
      <title>Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-reports-third-quarter-2025-financial-results-and-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-reports-third-quarter-2025-financial-results-and-business-updates</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Announced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell</description>
    </item>
    <item>
      <title>Sana Biotechnology to Present at the TD Cowen Immunology &amp; Inflammation Summit</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-present-td-cowen-immunology-inflammation-summit-2025-11-04</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-present-td-cowen-immunology-inflammation-summit-2025-11-04</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>SEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered</description>
    </item>
    <item>
      <title>Yellowstone Biosciences Appoints James (&quot;Jim&quot;) MacDonald as Chief Executive Officer</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/yellowstone-biosciences-appoints-james-jim-macdonald-as-chief-executive-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/yellowstone-biosciences-appoints-james-jim-macdonald-as-chief-executive-officer</guid>
      <pubDate>Tue, 16 Sep 2025 09:30:00 GMT</pubDate>
      <description>OXFORD, England, September 16, 2025--Yellowstone Biosciences Limited (&quot;Yellowstone&quot; or the &quot;Company&quot;), a pioneer of soluble bispecific T-cell receptor (TCR)-based therapies for human leukocyte antigen Class II (&quot;HLA Class II&quot;) targets in oncology, today announced the appointment of Jim MacDonald as its Chief Executive Officer and member of its Board of Directors.</description>
    </item>
    <item>
      <title>Sana Biotechnology to Present at September 2025 Investor Conferences</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-present-september-2025-investor-conferences-2025-08-26</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-present-september-2025-investor-conferences-2025-08-26</guid>
      <pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
      <description>SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered</description>
    </item>
    <item>
      <title>Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-closing-full-exercise-underwriters-option-purchase</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/sana-biotechnology-announces-closing-full-exercise-underwriters-option-purchase</guid>
      <pubDate>Wed, 20 Aug 2025 04:00:00 GMT</pubDate>
      <description>SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through</description>
    </item>
    <item>
      <title>eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors</title>
      <link>https://6ix.com/company/sana-biotechnology-inc/news/egenesis-appoints-douglas-williams-phd-and-adam-craig-md-phd-to-its-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/sana-biotechnology-inc/news/egenesis-appoints-douglas-williams-phd-and-adam-craig-md-phd-to-its-board-of-directors-1</guid>
      <pubDate>Tue, 19 Aug 2025 12:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., August 19, 2025--eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors</description>
    </item>
  </channel>
</rss>